Acrivon Therapeutics, Inc. Common StockACRV
▲ PositiveCapitalrelevance
Q2 GAAP EPS beat estimates and cash runway extended into Q4 2027.
Impact on stocks 1
Biotech & Genomic Medicine
Acrivon Therapeutics, Inc. Common StockAcrivon Therapeutics reported second-quarter 2026 GAAP EPS of negative $0.43, beating estimates by $0.07. As of June 30, 2026, the company had cash, cash equivalents and investments of $90.0 million, which is expected to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.
Acrivon Therapeutics, Inc. Common StockQ2 GAAP EPS beat estimates and cash runway extended into Q4 2027.